# Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

> **NCT01463423** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 256 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **RADIATION:** iSABR, 25 Gray in 1 fraction for small peripheral tumors
- **RADIATION:** iSABR, 50 Gray in 4 fractions for medium peripheral tumors
- **RADIATION:** iSABR, 54 Gray in 3 fractions for large peripheral tumors
- **RADIATION:** iSABR, 40 Gray in 4 fractions for small central tumors
- **RADIATION:** iSABR, 50 Gray in 4 fractions for medium central tumors
- **RADIATION:** iSABR, 60 Gray in 8 fractions for large central tumors

## Key facts

- **NCT ID:** NCT01463423
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-21
- **Primary completion:** 2020-01-02
- **Final completion:** 2022-02-07
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463423, "Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01463423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*